Shares of Danaher (DHR) tumbled 5.19% in pre-market trading on Tuesday following the company's release of its second-quarter 2025 results, along with disappointing full-year guidance and the announcement of a CFO transition plan.

Danaher reported Q2 adjusted earnings per share of $1.80, surpassing analysts' expectations of $1.64. Revenue for the quarter came in at $5.9 billion, slightly above the estimated $5.838 billion. However, the company's outlook for the rest of the year seems to have spooked investors. Danaher anticipates full-year adjusted revenue growth of just 3%, which appears to be below market expectations. The company also provided full-year adjusted EPS guidance of $7.70-$7.80, which falls short of the average analyst estimate of $7.70.

Adding to investor concerns, Danaher announced a transition plan for its Chief Financial Officer position. Matthew Gugino, currently the Group CFO of the company's Life Sciences Innovations Group, will succeed Matthew McGrew as Danaher's CFO effective February 28, 2026. While leadership transitions are normal, they can sometimes create uncertainty among investors, especially when coupled with less-than-stellar financial forecasts. The combination of these factors appears to be driving the significant pre-market sell-off in Danaher's stock.